Clinical trials
Neoadjuvant clinical trials
Below are recruiting neoadjuvant clinical trials, each written for real people, not researchers. We’re tracking 882 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07847710RecruitingPhase 2
Combination therapy before and after surgery for early liver cancer
This trial is testing a combination of two drugs (one that helps the immune system fight cancer and one that blocks blood vessel growth) with a special chemotherapy given directly into the liver. The goal is to shrink the tumor so it can be removed with surgery, possibly improving the chances of a cure.
Nanjing, JiangsuAges 18–75 - NCT06451393Recruiting
AI predicts stomach cancer response to chemo
This trial tests a computer-based model that uses CT scans, endoscopic images, and biopsy tissue to predict how well stomach cancer will respond to chemotherapy given before surgery. The goal is to help doctors choose the best treatment for each patient.
Guangzhou, GuangdongAges 20–90 - NCT06451211RecruitingPhase 2
Immuno-chemo before surgery for thick or large stomach cancers
This trial tests a combination of immunotherapy and chemotherapy given before surgery to shrink stomach cancers that are particularly thick or large. It aims to see if this approach can make these hard-to-treat tumors easier to remove and improve outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06463834RecruitingPhase 2
Sintilimab plus chemo before surgery for esophageal cancer
This study tests a combination of an immunotherapy drug (sintilimab) with chemotherapy given before surgery for a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Fuzhou, FujianAges 18–75 - NCT07829848Recruiting
Skip extra radiation for breast cancer patients who respond well to treatment
This trial tests whether women and men with advanced, non-metastatic breast cancer can safely skip an extra radiation boost to the lymph nodes if their tumors respond well to pre-surgery chemotherapy or targeted therapy. The goal is to reduce side effects while keeping cancer control.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06455410RecruitingPhase 2
GP plus adebrelimab vs. chemo alone for nasopharyngeal cancer
This trial tests a new combination of chemotherapy drugs (GP) plus an immunotherapy drug (adebrelimab) before standard treatment for nasopharyngeal cancer. It aims to see if this combination works better than chemotherapy alone for shrinking tumors.
Foshan, GuangdongAges 18–65 - NCT04135586Recruiting
Exercise program during chemotherapy for triple-negative breast cancer
This trial looks at whether a structured physical exercise program during neoadjuvant chemotherapy can help women with triple-negative breast cancer. You may qualify if you are treated at the specific hospital in Madrid and your tumor matches the required type and size.
MadridAges 25–75 - NCT06477991Recruiting
No surgery after immunotherapy for MSI-H colorectal cancer
This trial is studying whether some people with a specific type of advanced colorectal cancer (MSI-H/dMMR) might be able to skip surgery after immunotherapy. Doctors will use a blood test (MRD monitoring) to track the cancer, and then decide whether to keep an eye on it or operate.
Kunming, YunnanAges 18–75 - NCT04520737Recruiting
Exercise coaching during chemotherapy for liver metastases
This trial studies whether a “prehab” program—structured exercise and preparation—can help people keep up function while they are on chemotherapy for colorectal cancer that has spread to the liver. If you can safely exercise, the program may help you tolerate treatment and stay active.
TarragonaAges 18 years+ - NCT06485544RecruitingPhase 2
Immunotherapy before surgery for small cell lung cancer
This trial tests adding a drug called adebrelimab (a type of immunotherapy) before surgery for people with early-stage small cell lung cancer that can be removed. The goal is to see if it helps shrink the tumor and improve outcomes.
Xi'an, ShannxiAges 18–75 - NCT05635487RecruitingPhase 2
Neoadjuvant treatment for HER2-positive breast cancer with SHR-A1811
This trial tests whether SHR-A1811 alone, or together with pyrotinib, given before surgery, can shrink HER2-positive breast cancer. It may help you respond better to treatment while making surgery easier.
Shenyang, LiaoningAges 18–75 - NCT06487429RecruitingPhase 2
Short radiation followed by combo therapy for HER2+ stomach cancer
This trial tests a new approach for stomach cancer that has spread to nearby tissues but not to other organs. You would get a short course of radiation, followed by a combination of targeted therapy (Disitamab Vedotin), chemotherapy (S-1), and immunotherapy (Sintilimab) before surgery to shrink the tumor and improve outcomes.
Wuhan, HubeiAges 18–75 - NCT06492408RecruitingPhase 2
Immunotherapy before surgery for liver cancer
This trial tests giving two immunotherapy drugs directly into the tumor before surgery for liver cancer. It aims to see if this approach can shrink the tumor and improve outcomes for patients who are candidates for surgery.
Guanzhou, GuangdongAges 18–75 - NCT06492421RecruitingPhase 2
Immunotherapy before surgery for lung cancer
This trial tests whether giving two immunotherapy drugs directly into the tumor before surgery can shrink non-small cell lung cancer and improve outcomes. It is for people with early-stage (IIIA) lung cancer who are candidates for surgery.
Guanzhou, GuangdongAges 18–75 - NCT07804056RecruitingPhase 3
Alpha1H before surgery for low-risk bladder cancer
This study tests a new medicine called Alpha1H that is given before the usual surgery to remove bladder cancer. It may help lower the risk of the cancer coming back.
PragueAges 18 years+ - NCT06354140RecruitingPhase 2
Tislelizumab plus S-1 for esophageal cancer after surgery
This trial tests a combination of the immunotherapy drug tislelizumab and the chemotherapy drug S-1 for people with a specific type of esophageal cancer that still has some cancer cells in the main tumor but no cancer in lymph nodes after surgery. The goal is to see if this treatment can help prevent the cancer from coming back.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07802197Recruiting
Radiation before surgery for advanced rectal cancer
This trial compares giving radiation therapy before surgery versus going straight to surgery for people with advanced rectal cancer that has not spread to other parts of the body. It aims to see which approach may be better for controlling the cancer.
IstanbulAges 18 years+ - NCT07802002Recruiting
Dietary supplement to prevent bowel injury during radiation for rectal cancer
This trial tests whether a special dietary supplement can help protect the rectum from radiation damage during chemoradiation for locally advanced rectal cancer. If it works, it may reduce painful bowel symptoms like frequent stools and cramping.
Guangzhou, GuangdongAges 18–75 - NCT07808086Recruiting
Tumor bacteria in triple-negative breast cancer treatment response
This study looks at the bacteria found in the tumor to see if they affect how well chemotherapy or immunotherapy works in treating triple-negative breast cancer. The goal is to find ways to predict treatment response and improve care.
PaviaAges 18 years+ - NCT07797218RecruitingPhase 3
Comparing two drug combinations before breast cancer surgery
This study is comparing two different drug combinations given before breast cancer surgery. The goal is to see which one shrinks tumors more effectively. This type of treatment is called 'neoadjuvant' therapy.
ShanghaiAges 18–70 - NCT07796880RecruitingPhase 2
Study of a new drug with hormone therapy before breast cancer surgery
This trial tests a new drug called culmerciclib when given with hormone therapy before breast cancer surgery. The goal is to see if this combination can shrink tumors and improve outcomes for patients with hormone-receptor-positive, HER2-negative breast cancer.
Guangzhou, GuangdongAges 18–70 - NCT07796113RecruitingPhase 2
Study of adebrelimab plus famitinib and chemo before surgery for esophageal cancer
This trial tests a combination of an immunotherapy drug (adebrelimab) and a targeted therapy (famitinib) with chemotherapy before surgery for esophageal cancer. The goal is to see if this approach can shrink the tumor and improve surgical outcomes.
Xi'an, ShannxiAges 18–75 - NCT06530316Recruiting
RET inhibitor before surgery for advanced thyroid cancer with RET changes
This trial tests a targeted drug (a RET inhibitor) taken before surgery to help shrink thyroid cancer that has a specific genetic change (RET alteration). It may make surgery easier or more successful.
ShanghaiAges 14–80 - NCT06534489Recruiting
Surgery for lung cancer after chemo or targeted therapy
This trial tests whether combining chemo or targeted therapy before surgery can help people with non-small cell lung cancer that may require removing a whole lung. We want to see if this approach makes the surgery safer and more effective.
ShanghaiAges 18–75
Hear when a new Neoadjuvant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neoadjuvant?
- Yes. Clin2 currently lists 882 recruiting neoadjuvant studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neoadjuvant trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neoadjuvant trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.